Emergent BioSolutions – EBS – Received a multi-year grant from NIAID

Emergent BioSolutions Inc.(NYSE:EBS) announced that it has received a multi-year grant from theNational Institute of Allergy and Infectious Diseases(NIAID), part of theNational Institutes of Health, to advance the development of MVA85A, a candidate vaccine against tuberculosis (TB). The vaccine is being developed through a partnership between Aeras and theOxford-Emergent Tuberculosis Consortium(OETC), a joint venture between Emergent and theUniversity of Oxford, where the vaccine was originally developed and investigated.

MVA85A is now completing a Phase 2b clinical trial sponsored by Aeras to evaluate the safety and efficacy of the vaccine in over 2,700 infants inSouth Africa. Results from this trial, which has received continued funding from Aeras and theWellcome Trust, are anticipated later this year. MVA85A is also currently being studied in a second Phase 2b clinical trial, with primary funding and support from theEuropean and Developing Countries Clinical Trials Partnershipand Aeras, which will enroll approximately 1,400 adults living with the human immunodeficiency virus (HIV) inSenegalandSouth Africa.

“Emergent is honored to gain NIAID support, expanding the current government and non-government partners that are joining forces to advance this vaccine candidate. We all share a vision to declare victory in the global fight against tuberculosis and Emergent is proud to be at the forefront with such distinguished organizations,” said Daniel J. Abdun-Nabi, President and Chief Operating Officer ofEmergent BioSolutions. “With efficacy data expected in the coming months, we are hopeful that MVA85A will have a significant impact on the global burden of this highly contagious and lethal disease.”

According to theWorld Health Organization, approximately 1.5 million people die from tuberculosis annually, and more than two billion people are infected with TB – an estimated one out of every three people on the planet. It is the second leading cause of death from infectious disease worldwide. The limited efficacy against pulmonary TB of the only available licensed TB vaccine, Bacille Calmette-Guerin (BCG), and the rise of multi-drug and extensively-drug resistant TB cases, demonstrate the need for improved control measures against TB.

“We join the rest of the world in observing World TB Day onMarch 24, commemorating the discovery of the cause of the disease, the TB bacillus, that paved the way for the development of TB treatments, diagnostics, and vaccines,” said Dr.Jacqui Shea, General Manager of OETC. “Through much appreciated and essential grant funding, product development partnerships are making significant steps forward to stop TB. With continued support and collaboration, we hope to achieve our shared goal of a world free of TB within our lifetime.”

About EBS

EBS protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent’s marketed and investigational products target infectious diseases, oncology and autoimmune disorders.

More Posts by this author

• 
  Gold Prices Rise
• 
  Stocks End Higher
• 
  Stocks in Green in Late Trading
• 
  Gold and Silver Prices Remain in Green
• 
  Stocks Mixed after Housing Market Data
• 
  Advantage Oil & Gas Ltd. – AAV – Solid Financial & Operating Results
• 
  Silver Wheaton Corp. – SLW – Finished 2011 with its strongest ever quarter

Post Written By: Ed Liston Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing in his yacht.